Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Director Molly Harper Sells 17,500 Shares of Stock

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Director Molly Harper sold 17,500 shares of the firm’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total value of $385,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Catalyst Pharmaceuticals Trading Down 1.2 %

CPRX stock opened at $22.07 on Friday. The firm’s 50-day moving average price is $21.26 and its two-hundred day moving average price is $18.76. The stock has a market capitalization of $2.63 billion, a price-to-earnings ratio of 18.70, a PEG ratio of 3.44 and a beta of 0.75. Catalyst Pharmaceuticals, Inc. has a 12-month low of $13.00 and a 12-month high of $24.27.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Arizona State Retirement System raised its holdings in shares of Catalyst Pharmaceuticals by 2.2% during the second quarter. Arizona State Retirement System now owns 29,733 shares of the biopharmaceutical company’s stock valued at $461,000 after acquiring an additional 654 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Catalyst Pharmaceuticals by 62.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 681 shares in the last quarter. XTX Topco Ltd raised its stake in Catalyst Pharmaceuticals by 7.5% in the second quarter. XTX Topco Ltd now owns 11,134 shares of the biopharmaceutical company’s stock worth $172,000 after buying an additional 773 shares in the last quarter. Strategic Advocates LLC lifted its holdings in Catalyst Pharmaceuticals by 6.5% in the second quarter. Strategic Advocates LLC now owns 14,142 shares of the biopharmaceutical company’s stock worth $219,000 after buying an additional 864 shares during the period. Finally, Sei Investments Co. boosted its position in Catalyst Pharmaceuticals by 1.3% during the 2nd quarter. Sei Investments Co. now owns 84,458 shares of the biopharmaceutical company’s stock valued at $1,308,000 after acquiring an additional 1,098 shares in the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on CPRX. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th. Stephens initiated coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They set an “overweight” rating and a $35.00 price target on the stock. Truist Financial upped their price objective on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, November 11th. Citigroup upped their target price on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Finally, HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $31.14.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.